<DOC>
	<DOCNO>NCT00513526</DOCNO>
	<brief_summary>RATIONALE : Vaccines make human papillomavirus may help body build effective immune response kill HIV cell . PURPOSE : This phase II trial study side effect well human papillomavirus vaccine therapy work treat men HIV-1 infection .</brief_summary>
	<brief_title>Human Papillomavirus Vaccine Therapy Treating Men With HIV-1 Infection</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess safety tolerability quadrivalent human papillomavirus ( HPV ) ( type 6 , 11 , 16 , 18 ) recombinant vaccine HIV-infected men . - To assess immunogenicity quadrivalent HPV vaccine type 6 , 11 , 16 18 subject antibody-negative baseline . Secondary - To evaluate change plasma HIV-1 RNA CD4+ count vaccination series . - To describe association CD4+ count , nadir CD4+ count , age antibody response . - To evaluate level persistence HPV 6 , 11 , 16 , 18 antibody titer vaccination series among subject accord serostatus baseline . - To evaluate oral level serum IgA vaccination series . Tertiary - To evaluate prevalent incident HPV infection anal canal . - To evaluate cytological histological abnormality anal canal . - To evaluate prevalent incident HPV infection oral cavity . - To compare oral anal compartmental shed HPV vaccination . OUTLINE : This multicenter study . Patients receive quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine intramuscularly day 0 week 8 24 . After completion protocol therapy , patient follow 7 , 12 , 18 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : HIV1 infection , document licensed ELISA test kit confirm western blot prior study entry HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test Anal human papilloma virus DNA PCRnegative either type 16 and/or type 18 within 90 day prior entry If receive antiretroviral therapy : Receipt antiretroviral therapy least 6 month prior entry No change antiretroviral therapy within 30 day prior entry CD4 cell count &gt; 200 cells/mm³ within 90 day prior study entry HIV1 RNA &lt; 200 copies/mL within 90 day prior entry If receive antiretroviral therapy : CD4 cell count ≥ 350 cells/mm³ within 90 day prior study entry No plan start antiretroviral therapy prior week 28 Normal anal cytological result , atypical squamous cell undetermined significance lowgrade squamous intraepithelial lesion ( SIL ) result within 90 day prior entry Exclusion criterion : Current history anal perianal carcinoma Anal cytological result highgrade SIL ( HSIL ) , atypical squamous cell suggestive HSIL , suggestive invasive carcinoma screen history result Presence highgrade anal intraepithelial neoplasm ( HGAIN ) ( e.g. , AIN 2 3 , perianal intraepithelial neoplasia grade 2 3 ) , invasive carcinoma preentry , history HGAIN Current history anal perianal condyloma allow PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 70100 % Absolute neutrophil count &gt; 750 cells/mm³ Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm³ Creatinine clearance ≥ 60 mL/min AST ALT ≤ 3 time ULN Total conjugate ( direct ) bilirubin ≤ 2.5 time ULN Exclusion criterion : Serious medical psychiatric illness , active drug alcohol use , dependence , opinion site Investigator , would interfere adherence study requirement Serious illness require systemic treatment and/or hospitalization within past 45 day Allergy yeast component quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine Hemophilia PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Prior splenectomy Currently receive anticoagulation therapy acetylsalicylic acid Use systemic antineoplastic immunomodulatory treatment , systemic corticosteroid , investigational vaccine , interleukin , interferon , growth factor , IVIG within 45 day prior study entry Routine standard care , include hepatitis A B , influenza , pneumococcal tetanus vaccine exclude Hepatitis C coinfected patient eligible provided concurrent initiation treatment hepatitis C Prior receipt quadrivalent HPV ( type 6 , 11 , 16 , 18 ) recombinant vaccine HPV vaccine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>infection</keyword>
	<keyword>low-grade squamous intraepithelial lesion</keyword>
	<keyword>atypical squamous cell undetermined significance</keyword>
</DOC>